USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
BIOUSIAN BIOSYSTEMS, INC. (BBI)
Address:
51 FOLLEN RD
LEXINGTON, MA 02421
Phone:
N/A
URL:
N/A
EIN:
261543197
DUNS:
809896025
Number of Employees:
2
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $199,556.00 1
SBIR Phase II $992,331.00 1

Award List:

Novel Glycosylated Delta Opioid Receptor Agonists for Chronic Inflammatory Pain

Award Year / Program / Phase:
2009 / SBIR / Phase I
Award Amount:
$199,556.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Biousian Biosystems Inc. (BBI) intends to develop novel, glycosylated, deltorphin-based peptides as orally available drugs for the treatment of chronic inflammatory pain. By targeting a 4-selective mechanism, it is anti cipated that compounds with improved… More

Novel Glycosylated Delta Opioid Receptor Agonists for Chronic Inflammatory Pain

Award Year / Program / Phase:
2011 / SBIR / Phase II
Award Amount:
$992,331.00
Agency:
HHS
Principal Investigator:
Mark S. Kleven – 215-910-2261
Abstract:
DESCRIPTION (provided by applicant): Traditionally, Mu opioid receptor (MOR) agonists have not been given as first line treatments for neuropathic pain due to their significant adverse side effects. Biousian Biosystems Inc, (BBI) is developing novel glycosylated peptide-based delta opioid receptor… More